Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension

被引：0
|
作者：
Lucas M. Kimmig
Chuanhong Liao
Remzi Bag
机构：
[1] The University of Chicago Medicine,Section of Pulmonary and Critical Care Medicine
[2] The University of Chicago,Department of Public Health Sciences
[3] The University of Chicago,Biological Sciences Division
来源：
Lung | 2020年 / 198卷
关键词：
Pulmonary arterial hypertension; Prostacyclins; Prostanoids; Inhaled prostanoids; Transition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：53 / 58
页数：5
相关论文
共 50 条
  • [21] Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
    Hubert Chen
    Erika B Rosenzweig
    S Karl Gotzkowsky
    Carl Arneson
    Andrew C Nelsen
    Robert C Bourge
    Health and Quality of Life Outcomes, 11
  • [22] Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
    Chen, Hubert
    Rosenzweig, Erika B.
    Gotzkowsky, S. Karl
    Arneson, Carl
    Nelsen, Andrew C.
    Bourge, Robert C.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
  • [23] Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
    Benza, Raymond L.
    Seeger, Werner
    McLaughlin, Vallerie V.
    Channick, Richard N.
    Voswinckel, Robert
    Tapson, Victor F.
    Robbins, Ivan M.
    Olschewski, Horst
    Rubin, Lewis J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (12) : 1327 - 1333
  • [24] Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
    Song, Ci
    Kunovszki, Peter
    Beaudet, Amelie
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2022, 9 (01): : 151 - 160
  • [25] A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
    Zwicke, Diane L.
    Restrepo-Jaramillo, Ricardo
    Alnuaimat, Hassan
    Gordon, Kathryn
    Broderick, Meredith
    Edwards, Lisa D.
    Allmon, Andrew
    Leary, Peter J.
    PULMONARY CIRCULATION, 2021, 11 (01)
  • [26] Treprostinil in the treatment of pulmonary arterial hypertension
    Feldman, Jeremy
    Habib, Naomi
    Fann, Jade
    Radosevich, John J.
    FUTURE CARDIOLOGY, 2020, 16 (06) : 547 - 558
  • [27] Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension
    Papademetriou, Eros
    Liu, Xing
    Beaudet, Amelie
    Tsang, Yuen
    Potluri, Ravi
    Panjabi, Sumeet
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 644 - 655
  • [28] Treprostinil for the treatment of pulmonary arterial hypertension
    Torres, Fernando
    Rubin, Lewis J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (01) : 13 - 25
  • [29] The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension
    Pedersen, Mia Lindegaard
    Krueger, Marcus
    Grimm, Daniela
    Infanger, Manfred
    Wehland, Markus
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 (01) : 32 - 42
  • [30] Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension
    Radosevich, John J.
    DeChristopher, Audra
    Irandost, Maykel
    Fann, Jade
    Feldman, Jeremy
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (15) : 1208 - 1212
12345